Table 3—

High-resolution computed tomography (HRCT) findings, pulmonary function and pathology findings, according to tobacco smoking and treatment of rheumatoid arthritis

	Smokers		Methotrexate		Gold salts		d-Penicillamine		Smokers on ARD
	Yes	No	Yes	No	Yes	No	Yes	No	Yes	No
Subjects n	8	17	13	12	10	15	12	13	5	20
HRCT findings
Emphysema %	62	53	69	41	60	53	66	46	60	55
Alveolar consolidation %	25	29	23	33	20	33	17	38	20	35
Ground-glass attenuation %	50	41	61	25	50	40	50	38	60	40
Honeycombing %	12.5	17	230	8	10	20	17	15	0	20
Mosaic pattern %	50	53	61	41	40	60	50	53	40	55
Bronchiectasis %	37.5	41	53	25	30	46	42	38	40	40
Bronchial wall thickening %	100	94	92	100	80	100	91	100	100	95
Lung function findings
FEV₁ mL	1230±300	910±380	910±330	1160±380	930±430	1100±320	800±320**	1240±320**	1100±240	975±430
RV/TLC % pred	119±27*	151±23*	146±24	129±14	144±21	139±26	155±25	128±26	119±31	145±23
Pathological findings
Constrictive bronchiolitis n	3	3	4	2	2	4	4	2	4	2
Follicular bronchiolitis n	0	1	0	1	1	0	0	1	0	1
Mixed bronchiolitis n	1	1	1	1	2	0	2	0	2	0

Data are expressed as mean±sd, unless otherwise stated. HRCT, lung function and pathological characteristics are expressed in ex-smokers (compared with never-smokers), or in patients ever treated with methotrexate, gold salts or d-penicillamine, and in ex-smokers who had received anti-rheumatoid drugs (ARDs; as compared with the other patients). FEV₁: forced expiratory volume in one second; RV: residual volume; TLC: total lung capacity. *: p<0.05; **: p<0.01.